Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimatoprost SR vs Timolol in Open-angle Glaucoma or Ocular Hypertension
2024-519595-87-00Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised trial of bimatoprost in ocular hypertension and open-angle glaucoma (OAG) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Time-matched change in intraocular pressure at Hours 0 and 2 in the study eye. Started Dec 2024; status: completed.
02
Drugs
bimatoprost
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on 2024-519595-87-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519595-87-00.